Market capitalization | $431.89m |
Enterprise Value | $174.93m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.47 |
P/S ratio (TTM) P/S ratio | 8.57 |
P/B ratio (TTM) P/B ratio | 1.84 |
Revenue growth (TTM) Revenue growth | 34.98% |
Revenue (TTM) Revenue | $50.39m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 50 50 |
35%
35%
|
|
Gross Profit | 46 46 |
57%
57%
|
|
EBITDA | -98 -98 |
16%
16%
|
EBIT (Operating Income) EBIT | -99 -99 |
15%
15%
|
Net Profit | -87 -87 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Jay Duker |
Employees | 121 |
Founded | 1987 |
Website | www.eyepointpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.